Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled Phase IIa Trial to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BI 3810477 With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis

NCT07926321 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07926321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled Phase IIa Trial to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BI 3810477 With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 13, 2026
Completion date
April 20, 2028
Enrollment
70 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Placebo Placebo comparatorPlacebo
  • BI 3810477 ExperimentalBI 3810477

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Absolute change from baseline in forced vital capacity (FVC) [mL] at Week 12 At baseline and at Week 12.

Lead sponsor's other trials

Boehringer Ingelheim, most recent start first.

Similar trials

Same condition (Idiopathic Pulmonary Fibrosis) and phase, most recent start first.